Trial Profile
Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2021
Price :
$35
*
At a glance
- Drugs Marizomib (Primary)
- Indications Ependymoma
- Focus Therapeutic Use
- 01 Nov 2021 Status changed from completed to discontinued as the pharmaceutical company decided to close their program evaluating the study agent, Marizomib.
- 01 May 2021 Status changed from recruiting to completed.
- 24 Sep 2020 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.